The purpose of this study is to find a recommended dose level and schedule of dosing RXDX-109 (formerly LY2940680) that can safely be taken by patients with advanced cancer. The study will also explore the changes in a cancer marker level in skin, hair follicles, buccal cells, and tumor cells. Finally, the study will help document any antitumor activity this drug may have.